TICKERNOMICS Sign up
Last Update: 2024-03-28 02:12:42
Edgewise Therapeutics Inc. ( EWTX ) https://www.edgewisetx.com
17.14USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
EWTX
144.86%
SPY
32.74%
-42.87%
EWTX
SPY
92.93%
EWTX
0.00%
SPY
224.41%
EWTX
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
1207.57
956.24
0.58
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-14.43
0.00
3.79
-25.64
0.00
-8.83
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
0.00
0.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.27
-256.24
-34.97
0.00
Other Earnings and Cash Flow Stats:
Edgewise Therapeutics Inc. ( EWTX ) Net Income TTM ($MM) is -78.93
Edgewise Therapeutics Inc. ( EWTX ) Operating Income TTM ($MM) is -95.50
Edgewise Therapeutics Inc. ( EWTX ) Owners' Earnings Annual ($MM) is 0.00
Edgewise Therapeutics Inc. ( EWTX ) Current Price to Owners' Earnings ratio is 0.00
Edgewise Therapeutics Inc. ( EWTX ) EBITDA TTM ($MM) is -94.35
Edgewise Therapeutics Inc. ( EWTX ) EBITDA Margin is 0.00%
Capital Allocation:
Edgewise Therapeutics Inc. ( EWTX ) has paid 0.00 dividends per share and bought back -16.859589 million shares in the past 12 months
Edgewise Therapeutics Inc. ( EWTX ) has increased its debt by 1.006 million USD in the last 12 months
Capital Structure:
Edgewise Therapeutics Inc. ( EWTX ) Interest-bearing Debt ($MM) as of last quarter is 5
Edgewise Therapeutics Inc. ( EWTX ) Annual Working Capital Investments ($MM) are -25
Edgewise Therapeutics Inc. ( EWTX ) Book Value ($MM) as of last quarter is 318
Edgewise Therapeutics Inc. ( EWTX ) Debt/Capital as of last quarter is 1%
Other Balance Sheet Stats:
Edgewise Therapeutics Inc. ( EWTX ) has 86 million in cash on hand as of last quarter
Edgewise Therapeutics Inc. ( EWTX ) has 16 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Edgewise Therapeutics Inc. ( EWTX ) has 70 common shares outstanding as of last quarter
Edgewise Therapeutics Inc. ( EWTX ) has 0 million USD of preferred stock value
Academic Scores:
Edgewise Therapeutics Inc. ( EWTX ) Altman Z-Score is 33.19 as of last quarter
Edgewise Therapeutics Inc. ( EWTX ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
Edgewise Therapeutics Inc. ( EWTX ) largest shareholder is New Leaf Venture Partners, L.L.C. owning 1553661 shares at 26.63 ($MM) value
John R. Moore(an insider) Sold 8029 shares of Edgewise Therapeutics Inc. ( EWTX ) for the amount of $160660.29 on 2024-02-09
0.91% of Edgewise Therapeutics Inc. ( EWTX ) is held by insiders, and 109.41% is held by institutions
Edgewise Therapeutics Inc. ( EWTX ) went public on 2021-03-26
Other Edgewise Therapeutics Inc. ( EWTX ) financial metrics:
FCF:-78.15
Unlevered Free Cash Flow:-65.08
EPS:-1.46
Operating Margin:0.00
Gross Profit Margin:0.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-32.26
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Edgewise Therapeutics Inc. ( EWTX ) :
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company also develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The Company was incorporated in 2017 and is headquartered in Boulder, Colorado.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.